Table 1.
UCP | Rotterdam Study I | Rotterdam Study II | Rotterdam Study III | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Control | Case | p value | Control | Case | p value | Control | Case | p value | Control | Case | p value | |
Number | 2617 | 158 | 4117 | 1575 | 2021 | 129 | 2421 | 505 | ||||
Sex, % male | 71 | 53 | <0.001 | 47 | 27 | <0.001 | 46 | 31 | <0.001 | 42 | 54 | <0.001 |
Age mean, years (SD) | 58 (10.7) | 60 (11.1) | 0.009 | 68 (8.8) | 70 (8.6) | <0.001 | 65 (7.8) | 68 (9.1) | <0.001 | 57 (6.6) | 58 (7.4) | 0.007 |
Medication use, % | ||||||||||||
Beta-blockers | 79 | 58 | <0.001 | 15 | 13 | 0.080 | 15 | 16 | 0.519 | 14 | 17 | 0.096 |
Other antihypertensives | 77 | 65 | 0.001 | 14 | 12 | 0.042 | 1 | 2 | 0.055 | 0 | 1 | 0.053 |
Corticosteroids | 8 | 10 | 0.443 | 2 | 2 | 1.000 | 1 | 2 | 0.078 | 1 | 1 | 0.980 |
Bone-modifying drugs | 8 | 6 | 0.754 | 0 | 0 | NA | 1 | 2 | 0.262 | 1 | 3 | <0.001 |
Antidiabetic drugs | 31 | 18 | <0.001 | 4 | 5 | 0.093 | 5 | 8 | 0.025 | 4 | 6 | 0.354 |
Antidepressant drugs | 6 | 7 | 0.604 | 2 | 2 | 0.535 | 5 | 6 | 0.530 | 7 | 6 | 0.449 |
Antipsychotic drugs | 1 | 1 | 1.0 | 14 | 18 | <0.001 | 10 | 12 | 0.152 | 10 | 6 | 0.006 |
Antiepileptic drugs | 4 | 4 | 0.503 | 0 | 1 | 1.000 | 14 | 17 | 0.840 | 14 | 26 | 0.074 |
Sleep medication | 15 | 22 | 0.017 | 14 | 15 | 0.604 | 13 | 20 | 0.006 | 9 | 6 | 0.038 |
NSAIDs | 10 | 16 | 0.030 | 25 | 26 | 0.365 | 11 | 10 | 0.707 | 14 | 10 | 0.018 |
Immunosuppressive drugs | 1 | 3 | 0.125 | 0 | 0 | 1.000 | 0 | 0 | NA | 1 | 1 | 0.925 |
Characteristics of the cases and controls of the UCP and Rotterdam Study cohorts
NA not applicable